20 drug companies hit with lawsuit for inflating drug prices

Forty-four U.S. states have joined together in a lawsuit against 20 drug manufacturers, accusing them of scheme to inflate drug prices and eliminate competition in the market, Reuters reported. The drug makers are accused of jacking up the prices by more than 1,000% in some cases.

The lawsuit comes at a time when the Trump administration has made some moves to lower drug prices by forcing drug companies to publish prices in television ads. The administration is also mulling over regulations that would base Medicare Part B drugs, which are typically administered in a doctor’s office, on an international pricing scale. The new complaint is also parallel to another lawsuit filed in 2016 by 45 state attorneys general.

At the center of the scheme is Teva Pharmaceuticals USA, which plans to fight the lawsuit. The complaint filed by states argues that drug companies that produce generics have long engaged with each other ensure they all get a fair share of profits under the guise of being competitors.

From 2013 to 2015, drug companies “colluded to significantly raise prices on 86 medicines,” Reuters reported. These drugs included tablets, capsules, creams and ointments to treat diabetes, high cholesterol, high blood pressure, cancer, epilepsy and more. Humana has also filed a lawsuit for a drug price fixing scheme against drugmakers.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.